Conatus Pharmaceuticals Inc. (CNAT)
(Delayed Data from NSDQ)
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Allergan (AGN) Collaborates with Novartis to Treat NASH
by Zacks Equity Research
Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis
Are Options Traders Betting on a Big Move in Conatus Pharmaceuticals (CNAT) Stock?
by Zacks Equity Research
Conatus Pharmaceuticals (CNAT) warrants investors' attention based on moves in the options market lately.
Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) reported fourth-quarter 2016 loss of 35 cents per share, wider than both the Zacks Consensus Estimate of a loss of 32 cents and the year-ago figure of 30 cents.
Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) is expected to report fourth-quarter 2016 results next month.
Henry Schein Hurt by Higher Costs, Lacks Growth Drivers
by Zacks Equity Research
On Jan 10, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
Walgreens Teams Up with Fedex to Boost Retail Performance
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) recently inked a multi-year partnership agreement with global express delivery services company FedEx Corporation (FDX).
NuVasive at 52-Week High on Preliminary Results, MHLW Nod
by Zacks Equity Research
Share price of San Diego, CA-based NuVasive, Inc. (NUVA) scaled a new 52-week high of $71.03 on Jan 11, finally closing a tad lower at $70.7.
Can The Uptrend Continue for Conatus (CNAT)?
by Zacks Equity Research
Investors certainly have to be happy with Conatus Pharmaceuticals Inc. (CNAT) and its short term performance.
Align Poised On Global Expansion & Invisalign Teen Growth
by Zacks Equity Research
On Jan 10, 2017, we issued an updated research report on California-based Align Technology Inc. (ALGN).
Are Options Traders Betting on a Big Move in Conatus Pharmaceuticals (CNAT) Stock?
by Zacks Equity Research
Conatus Pharmaceuticals (CNAT) warrants investors' attention based on moves in the options market lately.
Company News for December 21, 2016
by Zacks Equity Research
CNAT,GIS,BBRY,FRED
Conatus Stock Up on Liver Drug Collaboration with Novartis
by Zacks Equity Research
Conatus (CNAT) inked an exclusive option, collaboration and license agreement with Novartis (NVS) for the worldwide development and commercialization of emricasan.